Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $44000.0.

  • Prestige Consumer Healthcare's Gains from Investment Securities changed N/A to $44000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year decrease of 2695.47%. This contributed to the annual value of $5.8 million for FY2025, which is 588.24% up from last year.
  • Prestige Consumer Healthcare's Gains from Investment Securities amounted to $44000.0 in Q4 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Gains from Investment Securities ranged from a high of $6.6 million in Q1 2021 and a low of $16000.0 during Q4 2022
  • For the 5-year period, Prestige Consumer Healthcare's Gains from Investment Securities averaged around $3.1 million, with its median value being $3.5 million (2021).
  • Examining YoY changes over the last 5 years, Prestige Consumer Healthcare's Gains from Investment Securities showed a top increase of 42258.06% in 2025 and a maximum decrease of 3011.55% in 2025.
  • Prestige Consumer Healthcare's Gains from Investment Securities (Quarter) stood at $2.9 million in 2021, then crashed by 99.45% to $16000.0 in 2022, then skyrocketed by 34325.0% to $5.5 million in 2023, then crashed by 99.44% to $31000.0 in 2024, then surged by 41.94% to $44000.0 in 2025.
  • Its last three reported values are $44000.0 in Q4 2025, $162000.0 for Q3 2025, and $4.1 million during Q2 2025.